Ocumetics Technology Corporation (QB)【OTCFF】株式ニュース

Here's the latest news release:

https://ocumetics.com/wp-content/uploads/2025/07/Ocumetics-Announces-Completion-of-First-Tranche-of-Private-Placement.pdf

Ocumetics Announces Completion of First Tranche of Unit Private Placement
For Immediate Release
Calgary, Alberta – July 17, 2025. Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV:
OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tranche of the private
placement previously announced by the Corporation on June 4, 2025 (the “Offering”).
The Corporation has issued an aggregate of 3,212,462 units (“Units”) at a price of $0.35 per unit for
aggregate gross proceeds of $1,124,362. Each Unit consists of one common share in the share capital of
the Corporation (“Common Share”) and one-half of one common share purchase warrant. Each whole
warrant (“Warrant”) entitles the holder to purchase one additional Common Share at an exercise price of
$0.50 for a period of 24 months from the date of issuance of the Warrant.
In connection with their services as agent under the first tranche of the Offering, the Corporation paid
$68,610 to Numus Capital Corp. (“Numus Capital”) and issued to Numus Capital warrants (“Agent’s
Warrants”) entitling Numus Capital to purchase up to an aggregate of 196,029 Common Shares at a price
of $0.50 per share for a period of 24 months.
The Warrants and Agent’s Warrants are subject to an acceleration clause such that if the volume weighted
average trading price of the Common Shares on the TSX Venture Exchange is at least $0.60 per Common
Share for a period of 30 consecutive trading days, the expiry date of the Warrants may be accelerated by
the Corporation to a date that is not less than 30 days after the date that notice of such acceleration is
provided to the Warrant holders by way of a press release.
The total offering is for of up to 6,000,000 Units at a price of $0.35 per Unit for gross proceeds of up to
$2,100,000. The Corporation intends to close the rest of the offering in one or more subsequent tranches.
100% of the net proceeds are expected to be used for ongoing research and development, although the
actual allocation of proceeds may vary from the uses set out above, depending upon future operations,
events or opportunities.
All securities issued under the Private Placement are subject to a hold period of four months and one day.
Closing of the Private Placement was subject to the conditional approval from the TSX Venture Exchange,
which was obtained.